Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.

A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with ...

What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.

Biomarker and preclinical data support SEZ6 as a potential therapeutic target in small cell lung cancer management.

In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.

In STARBOARD, frontline encorafenib, binimetinib, and pembrolizumab improved ORR and PFS vs pembrolizumab alone in BRAF V600E ...

Investigators of the CEMI-LUNG study (NCT05363319) enrolled an unselected, real-world population of more than 200 patients ...

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after ...

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

In KEYNOTE-412, early ctDNA clearance was linked with better survival with pembrolizumab plus chemoradiotherapy in ...

A biologics license application (BLA) for etentamig (ABBV-383) has been submitted to the FDA for the treatment of adults with ...

Translating laboratory discoveries into clinical benefit for patients with breast cancer increasingly depends on combining ...